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Aim: Evaluation of first experience of the di-
rectly observed therapy (DOT) programme for
tuberculosis introduced in the Canton of Vaud in
1997.
Method: Retrospective analysis of tuberculosis
patients included in a DOT programme from Oc-
tober 1997 to March 2000 under the supervision
of the TB Dispensary in Lausanne.
Results: 54 patients were included, 49 of whom
were new cases and 5 relapses. 70% were asylum
seekers and illegal immigrants. The indications for
DOT were immigrant status, social problems, and
physical or psychiatric comorbidities. Treatment
was fully supervised in 67% and partially in 33%.
The outcome was favourable (cure or treatment
completion) in 88.9% and unfavourable in 11.1%.
A similar success rate was observed in full and par-
tial DOT and there was no difference in success
rates between the various structures where DOT
was administered. By comparison, the success rate
in a historical group from the same institution was
70% in 1990.
The biggest problem was communication with
the patients and within the team.
Conclusion: Treatment of tuberculosis under
DOT in the Canton of Vaud resulted in improve-
ment of the treatment success rate. 
Key words: tuberculosis; directly observed treat-
ment; DOT; therapeutic adherence
Tuberculosis (TB) is on the decline in Swit-
zerland [1–2]. In 2003 the incidence was 8.6 per
100 000 population per year [3]. Since 1994 the
number of cases notified among foreign-born pa-
tients, especially asylum seekers from countries
with a high incidence, was higher than that ob-
served in the native Swiss population. 
Regularity and completeness is paramount in
the treatment of tuberculosis, since default, inter-
ruption and incorrect dosing may cause failure or
relapse and development of drug resistance. The
WHO reports worldwide success rates for tuber-
culosis treatment ranging from 20–87% [4]. Fac-
tors influencing the success rate relate to patient
adherence but also to the health care system (e.g.
adequate case management, drug availability).
Several studies have tried to define the factors as-
sociated with poor therapeutic adherence eventu-
ally resulting in an unfavourable outcome: age, sex
and nationality do not usually influence adherence
[5]; long and complex treatment, difficult access to
health care facilities, communication problems
between patients and health partners, physical or
psychiatric comorbidities, alcohol abuse or i.v.
drug consumption, social marginalisation and re-
lapse after prior TB treatment seem to be risk fac-
tors for decreased therapeutic adherence [5–7].
Many authors have proposed methods of improv-
ing the control of drug intake, such as blood or
urine tests to check the presence of the TB drugs
and electronic devices to monitor time of drug in-
take and improve adherence to TB treatment by
educating the patients and their families, incen-
tives (bus fares, meals etc), letters or phone calls to
recall appointments [6, 8]. Fixed drug combina-
tions have also been advocated as a means of mak-
ing treatment less complex [9]. All these methods
are effective to some degree when used separately. 
Directly observed therapy (DOT) has been
promoted as one method of ensuring regular in-
take of drugs until complete cure. Introduced by
Fox in the fifties, the method involves observing
the patient taking the drugs [10]. This ensures in-
take of the full treatment, regular follow-up of pa-
tients, early detection of adverse events and imme-
diate awareness of non-adherent patients who fail
to keep appointments. For some experts DOT
should be offered to all tuberculosis patients [11,
12]. Others consider that its effectiveness has not
been proven by controlled studies [13]. Its cost-ef-
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fectiveness has also been questioned, particularly
in relation to programmes attaining a high rate of
cure and completion. DOT is seldom used in low
prevalence countries in Europe and requires
highly coordinated teamwork. 
In our institution we have been using DOT
since 1997 for immigrants and for patients with so-
cial problems and physical or psychiatric comor-
bidities potentially associated with default and
non-compliance. We also included all cases in re-
treatment, with drug resistance or following inter-
mittent treatment (3 doses per week).
The aim of the study was to evaluate experi-
ence of the DOT programme in a region with a
low incidence of tuberculosis but a high propor-
tion of immigrants and potentially non-compliant
patients, in order to study the outcome of treat-
ment in tuberculosis patients on the basis of the
duration and location of DOT, and to compare the
outcome with data from the period preceding the
implementation of DOT.
Method
The DOT programme was introduced in the Canton
of Vaud in 1997, under the supervision of the TB Dispen-
sary of the Lausanne University Medical Policlinic. The
patients included in the programme were immigrants or
patients with severe psychiatric comorbidities (psychosis
etc.), alcohol or drug abusers, patients presenting social
problems (homeless, illegal immigrants, prison inmates),
and HIV-infected patients. We also included all the re-
treatment cases, the intermittent treatment cases and all
drug resistant TB. All patients were treated and followed
up according to Swiss guidelines [14, 15]. The inclusion
criteria remained the same throughout the study. 
Once a patient with tuberculosis was included in the
programme the medical staff of the dispensary decided on
the type of supervision according to the patient’s needs: ei-
ther supervision entirely at the dispensary (patients visited
the dispensary daily to take their TB drugs) or another
structure (social health structures with nurses visiting the
patients at home or patients coming to the centre, health
centres for refugees and asylum seekers and shelters with
nurses or social workers supervising treatment, general
practitioners, pharmacies, daily supervision by a family
member collecting the drugs weekly from the dispensary,
drug distribution in prison). We endeavoured to find a
structure located near the patient’s home or workplace.
Many treatments were started in the dispensary and later
transferred to another supervision structure if this was
more convenient to the patient. Women with small chil-
dren were usually visited at home by a nurse who could
not only deliver DOT to the mother but also preventive
chemotherapy to the children. The patients with the worst
social and psychiatric problems were supervised only at the
dispensary, where we could use the other structures of the
institution if patients did not appear in time (our pharmacy
and the emergency ward). In all cases of drug distribution
by an external structure the dispensary provided overall
supervision of treatment. All patients were usually fol-
lowed up monthly in the dispensary and staff were in reg-
ular contact with the other structures to ensure therapeu-
tic adherence. The nurses kept a file on all patients and the
type of DOT, and kept a daily record of the doses given.
Dispensary nurses phoned or visited patients at the work-
place or at home when they missed appointments. We
were able to hire interpreters to explain the treatment and
role of supervision to some non-French speaking patients.
Asylum seekers received bus fare to attend the dispensary.
If the nurses discovered other problems (social, financial),
they could refer the patients to social workers. In very
compliant patients with negative cultures and stable social
conditions the treatment was self-administered after the
intensive phase.
All the patients who were started in the DOT pro-
gramme from October 1997 to March 2000 and had ended
treatment by March 2001 were included in this retrospec-
tive study. Data was collected at least 6 months after com-
pletion of treatment. We analysed the patient records and
contacted all the supervisors to discuss the problems that
had occurred during treatment. We analysed the popula-
tion included in the study and the treatment outcome in
patients treated under full DOT (whole duration of treat-
ment), partial DOT (intensive phase only, i.e. 2 months),
and patients treated in a single institution (TB Dispensary)
or in other institutions under the Dispensary’s supervision.
Definitions
Therapeutic success is the sum of cases cured (with bac-
teriological confirmation) and those who received a full
course of treatment (without bacteriological confirmation of
cure) [16, 17].
The unfavourable outcomes are represented by thera-
peutic failure (sputum still positive after 5 months of treat-
ment), defaulters (interruption of treatment for more than
2 months), death (whatever the cause) and transfer (patient
transferred out of our health care system leaving us no pos-
sibility of ascertaining the result of the treatment). Relapse
is defined as a new diagnosis of TB in a patient who was
declared cured or who had completed a full course of treat-
ment.
Full DOT is treatment supervised throughout its
course. Included in this group were patients who received
at least 5 doses under supervision during the week and the
weekend doses in self-administration. Intermittent treat-
ments (3 times a week) were always administered under
full DOT. We define as partial DOT the courses with
supervision during only part of the treatment, usually the
intensive phase.
Statistical analysis
Statistical analyses were performed by GraphPad In-
Stat version 3.05 (GraphPad Software, San Diego, Cali-
fornia). Comparison of results between different sub-
groups and with historical control groups was calculated
by Fisher’s exact test.
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Between 1997 and 2000, 54 patients among 
the 257 tuberculosis cases notified in the Canton
of Vaud (21%) were included in the DOT pro-
gramme. The patients’ demographics are shown in
Table 1. Most were asylum seekers or refugees
(62.9%) or foreign residents (24.1%) and born ei-
ther in the Balkans (24.1%) or in Africa (51.8%).
The mean age was 31.6 years (range 15–74) (Fig.
1). Of the 203 patients not included in the DOT
programme 37 were followed up by the Dispensary
Results
Demographics %
Patients 100.0
Males 57.4
Females 42.6
Birthplace
Switzerland 5.6
Balkan countries 24.1
Other European countries 3.7
Africa 51.8
South America 5.6
Asia 9.2
Immigration status
Swiss nationality 5.6
Foreign residents 24.1
Asylum seekers and refugees 62.9
Illegal immigrants 7.4
Table 1
Demographics of 54
patients under DOT.
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Figure 1
Age distribution 
of patients treated
under DOT, 
by gender.
and 166 by other medical structures (chiefly gen-
eral practitioners).
The main comorbidities were 11 HIV infec-
tions (including one with cerebral toxoplasmosis),
9 psychiatric disorders, 6 alcohol abusers, 5 preg-
nancies and 3 IV drug users. 
Disease: Types of TB are reported in Table 2.
Most patients were smear- or culture-positive
(53.7%) and 9.3% were on retreatment. Among
new cases, two patients had received preventive
chemotherapy. Among the retreatment cases, no
patient had received the first course of treatment
under supervision. There were 3 cases of resistance
to antibiotics, one of which was multiresistant.
The smear- and culture-negative patients had
been diagnosed on the basis of clinical and radio-
logical criteria.
Treatment: Treatment was administered ac-
cording to the usual recommendation of 2 months’
intensive phase with HRZE (H = isoniazid, R = ri-
fampicin, Z = pyrazinamide, E = ethambutol) and
4 months’ continuation with HR, and was adapted
if necessary according to drug sensitivity, side ef-
fects and contra-indications. The mean duration of
treatment was 6.5 months. Seventeen treatments
were longer (maximum 21 months), chiefly due 
to use of second line antibiotics (resistance, side 
effects) or concomitant HIV infection. Six treat-
ments were shorter (1–5 months), due to default,
death or transfer.
Supervision: Supervision was complete in 36
cases (67%) and partial in 18 cases (33%). The pro-
portion of patients under partial DOT increased
from 22.2% in 1997 to 36.4% in 2000. Mean du-
ration of supervision was 4.6 months.
The indication for DOT was chiefly social
status (refugee, asylum seeker, illegal immigrant)
(74%) and language problems which were often
associated conditions. Patients under intermittent
therapy, retreatment, drug-resistant TB, smear-
positive cases who left hospital before sputum
became negative, and patients who had been non-
adherent during previous treatment or during hos-
pitalisation were always included in the DOT
programme. Several associated conditions such as
HIV infection, psychiatric disorders, alcohol or
drug abuse were also indications for DOT. Many
patients had more than one indication.
For 27 patients DOT was administered only
by the Dispensary, 10 by both the Dispensary and
another structure (pharmacy, family, prison, social
health structures), 13 by social health structures
only and 4 by other structures (general practition-
ers, asylum seeker centres). 
Treatment outcome: Overall the outcome was
favourable in 48 patients (17 cured and treatment
completed in 31) i.e. 88.9% of cases. There were 6
unfavourable outcomes (3 defaulters, 2 transfers
out and 1 death) i.e. 11.1% of cases. There were no
treatment failures. During the 31⁄2 years of the
Type of TB %
New cases
S+ pulmonary 33.3
S-/C+ pulmonary 14.8
S-/C- pulmonary 25.9
Extrapulmonary 16.7
Retreatment
S+ pulmonary 3.7
S-/C+ pulmonary 1.9
S-/C- pulmonary 0
Extrapulmonary 3.7
Table 2
Type of tuberculosis
among 54 patients
under DOT.
S = smear, 
C = culture
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study we observed one relapse. All cases in retreat-
ment and the patients with drug-resistant TB were
treated successfully.
A similar success rate was observed in the
partial and full DOT groups (Fig. 2). There was 
no statistical difference between the two groups 
(p = 1.00).
Allocation of patients to the two successful cat-
egories “cured” and “treatment completed” de-
pends on the result of the initial bacteriological ex-
amination. The proportion of patients cured and
treated completely differs between the two groups
because more patients with culture- or smear-pos-
itive TB were included in the full DOT group. 
The success rate in the group supervised by the
TB Dispensary alone was 92.6% vs 85.2% in the
group supervised by TB Dispensary and other
structures (Fig. 3). This difference was not statis-
tically significant (p = 0.67).
The 2 patients transferred out had very good
therapeutic adherence during the initial phase of
treatment. They had to leave Switzerland and re-
ceived sufficient antibiotics to complete the treat-
ment in their own countries.
The 4 other unfavourable outcomes had sev-
eral associated conditions such as HIV infection,
severe psychiatric disorders, alcohol and drug
abuse or other social problems (imprisonment). In
two cases the patients disappeared and could not
be traced.
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Figure 2
Outcome of treat-
ment by duration 
of DOT.
Full DOT = whole 
duration of treat-
ment. Partial DOT =
intensive phase only.
Favourable outcome
(cured and treatment
completed) is similar
for both groups
(88.9%), with no 
statistical difference
(p = 1.00).
Outcome by type of supervision
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Figure 3
Outcome of treat-
ment by type of 
supervision.
TBD alone = DOT ad-
ministered only by
TB Dispensary.
TBD and other = DOT
administered by TBD
and other structures
(social health struc-
tures, asylum seeker
health centres, phar-
macies, general prac-
titioners, families,
prison etc).
Favourable outcome
(cured and treatment
completed) is 92.6%
for TB Dispensary
alone and 85.2% for
TBD and other struc-
tures, with no statisti-
cal difference be-
tween the two
groups (p = 0.67).
Discussion
According to the World Health Organization
a TB programme should attain a success rate of
more than 85% [16, 18]. In low-endemic countries
the target is even higher and aims not only to lower
TB incidence but eventually eliminate the disease;
the rate of unfavourable outcomes should be under
10% after exclusion of death cases [19].
A programme should provide adequate case
finding and diagnosis, health care accessibility, a
continuous drug supply, regular follow-up of pa-
tients to ensure therapeutic adherence and a record
of the outcome (all these conditions are sum-
marised under the acronym DOTS). After analy-
sis of many programmes which did not reach the
WHO target, consideration was given to ways of
improving adherence [5–7, 10–12, 20–22]. Di-
rectly observed therapy has been introduced in nu-
merous TB programmes to enhance adherence
and so increase the success rate. 
In Switzerland DOT was first considered un-
necessary in view of the highly developed health
care system and as an intolerable limitation of pa-
tients’ rights. Several studies in the nineties re-
vealed that the WHO target of 85% was not being
reached: the success rate was 70% in the Canton
of Vaud [23] and 71% in Zurich [24]. An overall
success rate of 79% was observed in 1996 but the
rate was much lower (54%) among illegal immi-
grants [25]. In some studies asylum seekers were
also associated with a lower success rate [23, 26].
In view of these results, DOT was proposed to en-
sure adherence in some patient groups considered
at higher risk of decreased adherence, i.e. chiefly
immigrants and patients with social or psychiatric
comorbidities [14, 15, 27]. A first study analysed
the results of a DOT programme introduced in the
Canton of Zurich between 1991 and 1993, for the
population considered at high risk of non-adher-
ence [28]. The success rate increased from 59% in
the first year to 73% in the third year of the study.
Implementation of this new programme gradually
became more effective, though not reaching the
WHO target.
Our study shows that implementation of a
DOT programme is possible in a population con-
sidered at risk of decreased adherence. The success
rate in this group (88.9%) reaches the WHO tar-
get of 85% and even the target for low-incidence
countries after exclusion of death cases (90.6%).
The treatment results of the 203 patients not
included in the DOT programme were not known.
As the study was retrospective and there is no pro-
vision for systematic recording of the outcome of
treatment in Switzerland, the patients treated out-
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side our institution by other doctors could not be
traced and we did not have sufficient information
on follow-up of the patients treated in our institu-
tion without DOT. Moreover, these patients had
different demographic characteristics and so could
not serve as a valid comparison. We therefore had
to rely on historical comparison with the results
obtained from former studies performed locally.
The staff, the treatment and the characteristics of
the patients in this historical comparison bore a
closer resemblance than the group of patients
treated in the Canton of Vaud without DOT dur-
ing the period of the DOT study. The outcome of
treatment under DOT is superior to the historical
results previously obtained in the same region [23]
(success rate 88.9% vs 70%). This difference was
statistically significant (p = 0.007). The success rate
was enhanced under DOT with an odds ratio of
3.43 (95% CI 1.35–8.73). 
Coulon’s study pointed to several difficulties
with the treatment of immigrants. With the DOT
programme, patients who are often unstable (lan-
guage problems, frequent changes of residence,
financial difficulties) were followed more closely,
wherever possible with the help of interpreters,
and this contributed to an increase in the success
rate. The awareness of the risk factors for non-ad-
herence and the need for better and closer follow-
up of these patients resulted in an improved out-
come not only within the migrant population but
also in other groups (e.g. subjects with psychiatric
disorders or alcohol or drug abusers).
Several studies in other countries have
analysed the impact of DOT on the outcome of
TB treatment. The results are divergent. In some
randomised studies the outcome is no better with
DOT than with self-administered treatment [13].
Zwarenstein in rural South Africa reported no ad-
vantage from DOT [29]. However, the success rate
in that study was very low in both DOT and self-
administered treatment and we may therefore pre-
sume that other factors influenced these results
[30]; for example, there was no recall for patients
in the DOT group who missed an appointment. In
Pakistan, the outcome in patients supervised by
health centres or family members was similar to
that in self-administered treatment [31]. On the
other hand, American [32, 33]and other Asian [34,
35] studies report a significant increase in success
rate after implementation of DOT (25–55% be-
fore DOT compared to 70–90% with DOT pro-
grammes) and also a significant decrease in relapse
rate and resistance to antibiotics [36, 37].
Many authors insist on the fact that to increase
adherence [8, 38] the programme must be tailored
to patients’ needs. In our programme we endeav-
oured to adjust the type of supervision and its dura-
tion to the needs of the patient. Most patients were
supervised throughout treatment. For a third of
them we stopped supervision earlier, usually at the
end of the intensive phase, when the first part of the
treatment had been followed without major difficul-
ties and with good adherence. We continued to fol-
low up these patients monthly at the dispensary. The
final outcome in this group was the same as the
group supervised throughout treatment (success
rate 88.9% in both groups), with no statistical dif-
ference between the two groups. This suggests that
it would be possible to taper off supervision in a se-
lected number of patients without unfavourable
consequences for the outcome. However, as de-
scribed in an American study [37], we must be aware
that this involves a risk of lowering the success rate.
In this study, the success rate of partial DOT was
only 78–82% vs 85–87% under full DOT. 
We found no statistical difference between the
different types of supervision (TB Dispensary alone
vs TB Dispensary and other structures). The other
structures could not be analysed separately since the
number of patients followed in each structure was
too small.
The biggest problem was communication. Not
only communication with the patients, most of
whom did not speak French, but also within the
health care system. This led to errors in therapeu-
tic regimen and some brief treatment interruptions
because the Dispensary and the external structures
omitted to transmit information. One pharmacy did
not report bad adherence to the Dispensary and one
patient was lost to follow-up. Eight patients were ir-
regular in their visits to the Dispensary. After phone
calls or visits by the nurses at the patients’ workplace
the situation improved and treatment could be con-
tinued. The use of incentives (for instance bus fare
to travel to the dispensary), and the involvement of
interpreters and social workers if other problems
occurred (financial etc) helped to follow up patients
and continue treatment not only with regard to TB
therapy but psychosocial conditions.
The unfavourable outcomes included two
transfers. These patients adhered well to DOT at
the beginning of treatment and left Switzerland
with a sufficient supply of drugs to complete the
treatment in their own countries. Considering the
good adherence at the beginning, we can assume
that they have continued to take their drugs, in
which case the success rate would even attain 92.6%.
The other four unfavourable outcomes were in pa-
tients who had multiple other somatic or psychiatric
disorders, alcohol or drug abuse and social prob-
lems. Awareness of these problems should prompt
staff to follow up these patients even more closely
and endeavour to help them not only to take their
drugs but if possible also with their other problems.
For example, one alcoholic patient was hospitalised
after irregular Dispensary follow-up of simultane-
ous treatment for TB and alcohol cessation, and the
treatment was eventually successful. In nearly all
cases the unfavourable outcomes seem to be due to
factors other than defects in the programme itself
(death from HIV complications, severe psychiatric
disorder, illegal immigration, judicial problems).
Only in one case may the lack of rapid communica-
tion between pharmacy and dispensary have con-
tributed to inadequate follow-up of a patient. 
As the overall TB incidence is declining in
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Switzerland and the disease is increasingly diag-
nosed only in groups of patients from high-endemic
countries or with comorbidities such as HIV, there
is a danger that the general practitioner will experi-
ence difficulties in managing the patients under
treatment. The role of specialised TB centres which
can supervise programmes, update guidelines and
deliver regular information is crucial in this situa-
tion [39].
Another problem we met with during the study
was a lack of information on the outcome of treat-
ment. TB is an infectious disease notifiable by law,
and hence all cases occurring during the study pe-
riod were recorded. Though in the Dispensary the
nurses recorded drug intake daily, this was not done
as systematically in the other structures. In some
cases we had only oral information from the super-
visors about completion of treatment. To improve
follow-up of patients, it may be useful to record ad-
herence and treatment outcome more systemati-
cally. 
Conclusion
The implementation of DOT in selected TB
patients in our country is possible by use of the pre-
existing medical and social structures, and may im-
prove the success rate of TB treatment. Under the
DOT programme the TB treatment success rate
reaches the WHO target. DOT was not only
watching the patients as they swallowed their
drugs but also pursued a policy of following pa-
tients on an overall basis and identifying problems
(in relation to the disease, the treatment or pa-
tients’ social or financial situation) which may in-
terfere with TB treatment. DOT can be used in
programmes which focus not only on TB treat-
ment but also on the medical and psychosocial his-
tory of the patients, and can be tailored as far as
possible to the patient’s needs.
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Erratum
In issue 29–30 (Swiss Med Wkly 2004;134:
430–4), we regret that, by error, the article
“Oguzulgen IK, Ozis T, Gursel G. Is the fall in
platelet count associated with intensive care unit
acquired pneumonia?” was given the wrong cate-
gory heading. The correct heading is not “Short
communication” but “Original article”. We apol-
ogize to the authors for this oversight.
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